Nurix Therapeutics, Inc. (NRIX) Stock

HealthcareBiotechnology Website

NRIX has an Alpha Score of 55 out of 100 (weak), computed on Nov 9, 2026 from 3 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported NRIX in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is ARK Invest's at $43.92M. Company insiders reported 0 open-market buys and 15 sales on SEC Form 4 in the 90 days to Nov 13, 2026. Its trailing P/E ratio is 9.9 and its net margin 42.0% (key statistics as of Nov 2, 2026).

$15.48
-0.77%
Last price
Source: Finnhub
Alpha Score
55
Weak

What is NRIX's Alpha Score?

How it works →

Alpha Score of 55 reflects moderate overall profile with poor momentum, strong value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
9
Poor
Value
84
Strong
Quality
100
Strong

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 9, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which hedge funds own NRIX?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
ARK Invest
Cathie Wood
1.85M$43.92M+3%
Citadel
Ken Griffin
1.48M$35.83M+10%
Marshall Wace873K$20.69MNEW
D.E. Shaw
David Shaw
185K$4.48M-46%
Point72
Steve Cohen
73K$1.77M-84%
Millennium Management
Israel Englander
21K$507.3K-96%

13F holdings as of Sep 30, 2026

Explore all tracked funds →

Are Nurix Therapeutics, Inc. insiders buying or selling?

SEC Form 4 filings
90 days to Nov 13, 2026
Buys
0
Sells
15
Net $
-$1.7M
Unique insiders
4
DateInsiderRoleTypeSharesValue
Nov 4, 26Van Houte HansChief Financial OfficerSELL3.3K$51K
Nov 4, 26Van Houte HansChief Financial OfficerSELL1.5K$24K
Nov 3, 26Ring ChristineChief Legal OfficerSELL6.1K$158K
Nov 2, 26Hansen GwennChief Scientific OfficerSELL1.5K$39K
Nov 2, 26Ring ChristineChief Legal OfficerSELL9.5K$245K
Nov 2, 26Ring ChristineChief Legal OfficerSELL1.1K$29K
Oct 30, 26Hansen GwennChief Scientific OfficerSELL4.0K$104K
Oct 30, 26Ring ChristineChief Legal OfficerSELL4.0K$104K
Oct 30, 26Van Houte HansChief Financial OfficerSELL2.8K$74K
Oct 15, 26Hansen GwennChief Scientific OfficerSELL1.5K$36K

SEC Form 4 filings as of Nov 13, 2026

See cluster-buy signals across all tickers →

What are NRIX's key statistics?

P/E Ratio
9.93
EPS (TTM)
2.31
Beta
1.76
Net Margin
42.01%
ROE
49.34%
Debt / Equity
0.00
52W High
$28.23
52W Low
$11.50

Key statistics as of Nov 2, 2026

How does NRIX's valuation compare with the Healthcare sector?

MetricNRIXHealthcare medianCompanies in median
P/E ratio9.928.4125
Net margin42.01%3.53%193
Return on equity49.34%2.93%220

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 15, 2026). P/E excludes loss-making companies.

NRIX price chart

Powered by TradingView

What does Nurix Therapeutics, Inc. do?

Nurix Therapeutics Inc. is a biotechnology firm focused on developing therapies to address immune system disorders and cancers. At the heart of its innovative approach is the modulation of protein levels within cells, a critical factor in disease progression. Nurix employs its proprietary DELigase platform to discover and design targeted therapies that either enhance or degrade specific proteins through ubiquitin proteasome system engagement. By manipulating the protein degradation pathways, the company aims to offer new treatment paradigms where traditional therapeutics may fall short. Nurix Therapeutics' research and product pipeline significantly influences the biotechnology and pharmaceutical sectors, with emphasis on immuno-oncology, a rapidly growing field within cancer treatment. Formed through scientific expertise and collaborations, the company encapsulates significant market insights by translating breakthroughs in protein homeostasis into potential life-altering therapies, thus playing a pivotal role in advancing personalized medicine.

CEO
Dr. Arthur T. Sands M.D., Ph.D.
Employees
317
Market Cap
$2.93B
Ask about NRIXAI research agent